Michael R. Hayden, Director at AbCellera Biologics Inc. (ABCL), bought 461,312 shares at $20.00 ($1.6M) on 2020-12-15, disclosed to the SEC on 2020-12-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.33 | 270,000 | $89K | 5.7% |
| 2 | $0.00 | 117,647 | $0 | 0.0% |
| 3 | $20.00 | 73,665 | $1.5M | 94.3% |
| Total | $3.39 avg | 461,312 | $1.6M | 100% |
| Filing → |
| IONS | BUY | 2026-07-31 | $1.1M | — | Filing → |
| IONS | BUY | 2025-05-02 | $478K | — | Filing → |
| IONS | BUY | 2024-12-26 | $272K | — | Filing → |